Tag Archives: Aphria Inc

Aphria Inc Receives a Buy from Canaccord Genuity

In a new note to investors today, an analyst has provided a rating update for the Healthcare company, Aphria Inc (TSXV: APH). Analyst Matt Bottomley from Canaccord Genuity reiterated a Buy rating, with a C$26.50 price target. Bottomley wrote: “We

Aphria Inc Gets a Buy Rating from Clarus

Aphria Inc (TSXV: APH), the Healthcare company was revisited yesterday, and remains undervalued for at least one analyst on the street. The company received a Buy rating from Clarus’ analyst Noel Atkinson, with a C$25.25 price target. Atkinson observed: “We

Aphria Inc Receives a New Rating from a Top Analyst

In a latest note to investors, a research analyst has provided a rating update for the Healthcare company, Aphria Inc (TSXV: APH). Analyst Matt Bottomley from Canaccord Genuity rated Aphria Inc (TSXV: APH) a Buy on today, setting a C$23.50

Canaccord Genuity Believes Aphria Inc (TSXV: APH) Still Has Room to Grow

Aphria Inc (TSXV: APH), the Healthcare company was revisited today, and remains undervalued for at least one analyst on the street. The company received a Buy rating from Canaccord Genuity’s analyst Matt Bottomley, with a C$23 price target. According to

Aphria Inc Receives a Rating Update from a Top Analyst

In a latest note to investors, a research analyst has provided a rating update for the Healthcare company, Aphria Inc (TSXV: APH). Analyst Noel Atkinson from Clarus rated Aphria Inc (TSXV: APH) a Buy on today. Atkinson said: “We have

Clarus Believes Aphria Inc (TSXV: APH) Still Has Room to Grow

Wall Street analyst has provided a review for the Healthcare company today, but retained the same rating on the stock. Analyst Noel Atkinson from Clarus rated Aphria Inc (TSXV: APH) a Buy, setting a C$13 price target. Atkinson noted: “We